Recent Finacing
Recent Raise
PURMX Therapeutics develops unmodified microRNA-based therapeutics, advancing MIRX002 (miR-3140-3p with A6K carrier) in a Phase I mesothelioma trial and using Hiroshima University's RNA screening to generate additional RNA assets.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
